We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Polyplus-transfection to Supply RNAi Therapeutic Delivery Technology to Alnylam Pharmaceuticals
News

Polyplus-transfection to Supply RNAi Therapeutic Delivery Technology to Alnylam Pharmaceuticals

Polyplus-transfection to Supply RNAi Therapeutic Delivery Technology to Alnylam Pharmaceuticals
News

Polyplus-transfection to Supply RNAi Therapeutic Delivery Technology to Alnylam Pharmaceuticals

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Polyplus-transfection to Supply RNAi Therapeutic Delivery Technology to Alnylam Pharmaceuticals"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Polyplus-transfection has signed a collaboration agreement with Alnylam Pharmaceuticals, the leading RNAi therapeutics company, based in Cambridge, Massachusetts.

Under the terms of the agreement, Polyplus-transfection will provide Alnylam with its RNAi therapeutic delivery solutions and share its expertise in formulation for siRNAs, the molecules that mediate RNAi, in vivo. Alnylam will evaluate Polyplus' formulations for delivery of RNAi therapeutics.

The companies believe the collaboration has the potential to bring about improvements in the delivery of siRNA therapies.

Although there has been significant progress in this area to date, creating delivery solutions for RNAi therapeutics remains an important component in realizing the full potential of this promising technology.

"As Alnylam is the leading RNAi therapeutics company, we at Polyplus-transfection are delighted to be collaborating with a firm at the cutting edge," said Joëlle Bloch, CEO of Polyplus-transfection.

"A big advantage of this relationship is that Polyplus-transfection will benefit from having its chemical carriers tested in several disease models while working with the most advanced target sequences and mixed chemical siRNA modifications from Alnylam."

Polyplus-transfection is developing several in vivo siRNA formulation solutions based on its lead compounds in vivo-jetPEI (now GMP available) and INTERFERin, as well as on an original RNA modification, sticky siRNA (ssiRNA).

Advertisement